Kevin J. Harrington
A5072284989- Head and Neck Cancer Studies
- Virus-based gene therapy research
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Viral gastroenteritis research and epidemiology
- Advanced Radiotherapy Techniques
- Cancer Diagnosis and Treatment
- Advanced MRI Techniques and Applications
- Salivary Gland Tumors Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- RNA Interference and Gene Delivery
- Cancer, Hypoxia, and Metabolism
- Head and Neck Surgical Oncology
- Viral Infectious Diseases and Gene Expression in Insects
- Radiomics and Machine Learning in Medical Imaging
- Dysphagia Assessment and Management
- Medical Imaging Techniques and Applications
- interferon and immune responses
- Colorectal and Anal Carcinomas
- Peptidase Inhibition and Analysis
- MRI in cancer diagnosis
- Oral health in cancer treatment
Royal Marsden NHS Foundation Trust
2016-2025
Institute of Cancer Research
2016-2025
Royal Marsden Hospital
2016-2025
NIHR Biomedical Research Centre at The Royal Marsden and the ICR
2016-2024
Institute of Cancer Research
2011-2024
National Institute for Health Research
2016-2024
Prisma Health
2024
Sutton Hospital
2024
University of London
2024
London School of Hygiene & Tropical Medicine
2024
Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.In randomized, open-label, phase 3 trial, we assigned, in 2:1 ratio, 361 patients whose disease had progressed within 6 months platinum-based to receive nivolumab (at dose mg per kilogram body weight) every 2 weeks...
Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients unresected stage IIIB IV melanoma randomized open-label phase III trial.Patients injectable that not surgically resectable were randomly assigned at two-to-one ratio intralesional or...
Xerostomia is the most common late side-effect of radiotherapy to head and neck. Compared with conventional radiotherapy, intensity-modulated (IMRT) can reduce irradiation parotid glands. We assessed hypothesis that parotid-sparing IMRT reduces incidence severe xerostomia.We undertook a randomised controlled trial between Jan 21, 2003, Dec 7, 2007, compared (control) IMRT. randomly assigned patients histologically confirmed pharyngeal squamous-cell carcinoma (T1-4, N0-3, M0) at six UK...
BackgroundThe incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity standard cisplatin treatment, but no randomised evidence exists efficacy strategy.MethodsWe did open-label controlled phase 3 trial at 32 head and neck centres Ireland, Netherlands, UK, patients aged 18...
Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating factor (GM-CSF) in stages IIIc and IV disease.Treatment involved intratumoral injection up 4 mL 10(6) pfu/mL JS1/34.5-/47-/GM-CSF followed 3 weeks later by 10(8) every 2 24 treatments. Clinical activity (by RECIST [Response Evaluation Criteria Solid Tumors]), survival, safety parameters were monitored.Fifty patients (stages...
Head and neck cancers, including those of the lip oral cavity, nasal paranasal sinuses, oropharynx, larynx nasopharynx represent nearly 700,000 new cases 380,000 deaths worldwide per annum, account for over 10,000 annual in United States alone. Improvement outcomes are needed patients with recurrent or metastatic squamous cell carcinoma head (HNSCC). In 2016, US Food Drug Administration (FDA) granted first immunotherapeutic approvals - anti-PD-1 immune checkpoint inhibitors nivolumab...
Abstract Purpose: To conduct a phase I clinical trial with second-generation oncolytic herpes simplex virus (HSV) expressing granulocyte macrophage colony-stimulating factor (Onco VEXGM-CSF) to determine the safety profile of virus, look for evidence biological activity, and identify dosing schedule later studies. Experimental Design: The was administered by intratumoral injection in patients cutaneous or s.c. deposits breast, head neck gastrointestinal cancers, malignant melanoma who had...
Highlights•Anti-CTLA-4 of hIgG1 and hIgG2 isotypes promote depletion intra-tumoral Treg cells•hIgG2 antibodies mediate in vivo cells via CD32a•Anti-CTLA-4 with enhanced Fc effector function improves therapeutic outcomes•The CD16-V158F SNP is associated response to ipilimumab inflamed tumorsSummaryWith the use a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that equivalent tremelimumab regulatory T (Treg) cell vivo, increasing CD8+ ratio promoting tumor rejection....
<h3>Background</h3> Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report final planned analysis of OPTiM, a randomized open-label phase III trial patients with unresectable stage IIIB–IVM1c melanoma. <h3>Methods</h3> Patients were 2:1 to receive intratumoral talimogene or subcutaneous recombinant GM-CSF. In addition overall survival (OS), durable response rate (DRR), objective (ORR), complete responses (CR), safety are also...
Intravenous infusion of oncolytic reovirus in patients leads to infection brain tumors, infiltration by cytotoxic T cells, and up-regulation PD-L1.